Welcome to our dedicated page for Primerica SEC filings (Ticker: PRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Primerica, Inc. (NYSE: PRI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Primerica is a financial services company serving middle-income households in North America, and its filings offer detail on how its term life insurance and investment and savings products businesses operate.
Among the most important documents for PRI are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically describe the company’s three primary segments—Term Life Insurance, Investment and Savings Products, and Corporate and Other Distributed Products—and explain how revenues, premiums, commissions and expenses are generated and reported. They also discuss the use of non-GAAP financial measures such as adjusted operating revenues, adjusted net operating income and diluted adjusted operating earnings per share.
Investors can also review current reports on Form 8-K, where Primerica announces material events such as quarterly results releases and the posting of supplemental financial information. These 8-K filings often reference non-GAAP reconciliations and provide links to additional data made available to investors.
For users tracking management and ownership activity, insider transaction reports on Form 4 and related beneficial ownership filings are accessible through the SEC system and can be reviewed alongside other PRI disclosures. Proxy statements on Schedule 14A, when available, typically address topics such as governance and executive compensation.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand segment performance, capital management decisions and adjustments related to non-GAAP measures. Real-time updates from EDGAR ensure that new Primerica filings, including 10-Ks, 10-Qs, 8-Ks and Forms 4, are added as they become available, allowing investors to follow PRI’s regulatory reporting history efficiently.
Form 144 filed for Primerica, Inc. (PRI) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $1,046,680.00. The shares were originally acquired as restricted stock awards on 02/21/2015. The filer previously sold 2,000 shares on 05/19/2025 under a 10b5-1 plan, generating gross proceeds of $560,739.40. The filing lists 32,391,333 shares outstanding for the issuer and states the sale will occur on the NYSE.
Primerica reported a Form 4 showing that Glenn J. Williams, who is listed as both a director and the Chief Executive Officer, disposed of shares on 08/12/2025. The filing records a sale of 2,500 shares of Common Stock at a weighted average price of $262.2035. After the reported sale, Mr. Williams is shown as beneficially owning 36,391.995 shares directly. The transaction is coded as a sale and the form was executed on 08/12/2025 by Stacey K. Geer as attorney in fact. The filer explains the weighted average reflects multiple trade prices ranging from $259.22 to $264.34.
Primerica, Inc. (PRI) filed a Form 144 notifying a proposed sale of 2,500 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an indicated aggregate market value of $645,675.00. The shares were acquired as Restricted Stock Units on 03/01/2025 and the filing lists an approximate sale date of 08/12/2025. The filing also discloses a prior 10b5-1 sale of 2,500 shares on 06/13/2025 generating gross proceeds of $647,591.25. Outstanding shares are shown as 32,391,333, making the proposed block a very small percentage of the company.
Primerica Q2 2025 10-Q highlights
- Revenue inched up 0.3% YoY to $793.3 million; commissions & fees rose 14% while net premiums grew 3.6%.
- Pre-tax income from continuing ops fell 14% to $234.5 million; net income declined to $178.3 million (-15%) as prior-year results contained a one-off $50 million insurance recovery.
- Diluted EPS from continuing ops dropped to $5.40 (-11%); total diluted EPS unchanged by discontinued Senior Health unit, which caused a $208 million loss in Q2 2024.
- Segment performance: Term Life pre-tax profit +5% to $155.0 million; Investment & Savings Products +6% to $79.4 million; Corporate & Other near breakeven versus $50.2 million profit last year.
- Capital returns: 2Q buybacks of $127 million and dividends of $34 million reduced diluted share count 4% YoY to 32.9 million; YTD repurchases total $251 million.
- Balance sheet: Assets $14.83 b (+2% YTD); equity $2.31 b (+2%). Cash fell to $621 million after $329 million financing outflows. AOCI improved by $63 million YTD on discount-rate and FX movements.
- Liquidity & cash flow: Operating cash flow solid at $360 million versus $384 million YTD 2024; investing cash outflow $100 million driven by portfolio reinvestment.
Bottom line: Core franchises showed modest growth, but elevated expenses and loss of 2024’s non-recurring gain compressed margins. Shareholder payouts remain aggressive, sustaining mid-teens ROE.